# Pleural Effusion

> Accumulation of serous fluid within the pleural space is **pleural effusion**.

> Accumulation of pus within the pleural space is **empyema**.

> Accumulation of blood within the pleural space is **haemothorax**.

> Accumulation of chyle within the pleural space is **chylothorax**.

## Causes

1. Common (_TB-CHIPS_)
   - Tuberculosis (**TB**)
   - **C**ancer (Malignant disease)
   - **H**eart failure
   - Pulmonary **i**nfarction
   - **P**neumonia ('parapneumonic effusion')
   - **S**ubdiaphragmatic disorders (subphrenic abscess, pancreatitis, etc.)
1. Uncommon (_MARCH UP_)
   - **M**yxoedema
   - **M**eigs syndrome (oarian tumour + pleural effusion)
   - **A**sbestos-related benign plueral effusion
   - Acute **r**heumatic fever
   - **C**onnective tissue diseases (particularly SLE and rheumatoid arthritis)
   - **H**ypoproteinaemia (nephrotic syndrome, liver failure, malnutrition)
   - **U**raemia
   - **P**ost-myocardial infarction syndrome

## Clinical Features

## Investigations

1. **Radiological investigations**
   - Classical appearance on erect PA chest X-ray: Curved shadow at the lung base, blunting the costophrenic angle and ascending towards the axilla
   - Need around 200 mL of fluid to detect on the X-ray
1. **Ultrasound**
   - A clear hypoechoic space is consistent with a transudate
   - The presence of moving, floating densities suggests an exudate
1. **CT scan**
   - Malignant or loculation is suspected
1. **Pleural aspiration and biopsy** (Ultrasound or CT-guided)
   - Biochemical analysis: To classify exudate or transudate
   - Cytological examination: To characterize the presence of inflammatory or malignant cells
   - Microbiological staining: To detect bacteria and mycobacteria
1. **Measurement of Adenosine deaminase (ADA)**: If TB is considered
1. **Video-assisted thoracoscopy**

## Management

### Therapeutic Aspiration

- ~~An effusion should never be drained to dryness before establishing a diagnosis~~
- _Removing > 1.5 L at a time has a small risk of re-expansion pulmonary oedema_
- Management of underlying causes

## Differences Between Exudate and Transudate

| Feature                         | Exudate                                                         | Transudate                                                                      |
| ------------------------------- | --------------------------------------------------------------- | ------------------------------------------------------------------------------- |
| **Definition**                  | Fluid with high protein content and cellular elements           | Fluid with low protein content and minimal cells                                |
| **Cause**                       | Increased vascular permeability (inflammation)                  | Increased hydrostatic pressure or decreased oncotic pressure (non-inflammatory) |
| **Protein Content**             | High (>3 g/dL)                                                  | Low (< 3 g/dL)                                                                  |
| **Cell Content**                | High, often inflammatory cells (e.g., neutrophils, lymphocytes) | Low, few or no cells                                                            |
| **Appearance**                  | Cloudy or turbid                                                | Clear or pale                                                                   |
| **Specific Gravity**            | >1.020                                                          | < 1.015                                                                         |
| **Lactate Dehydrogenase (LDH)** | High (>2/3 of the upper limit of normal for serum)              | Low (< 2/3 of the upper limit of normal for serum)                              |
| **Cholesterol Levels**          | Elevated                                                        | Low                                                                             |
| **Common Causes**               | - Infections (e.g., pneumonia, TB)                              | - Heart failure (elevated hydrostatic pressure)                                 |
|                                 | - Malignancy                                                    | - Nephrotic syndrome (decreased oncotic pressure)                               |
|                                 | - Autoimmune diseases (e.g., rheumatoid arthritis, SLE)         | - Liver cirrhosis                                                               |
|                                 | - Trauma                                                        | - Hypoalbuminemia                                                               |
| **Light's Criteria\***          | Meets at least one criterion                                    | Does not meet any criterion                                                     |

## Anti-TB Treatment

### Dosage

| Drug           | Abbreviation | Dose (mg/kg/day) | Max Daily Dose |
| -------------- | ------------ | ---------------- | -------------- |
| `Isoniazid`    | H            | 10 mg/kg         | 300 mg         |
| `Rifampicin`   | R            | 15 mg/kg         | 600 mg         |
| `Pyrazinamide` | Z            | 35 mg/kg         | 2 g            |
| `Ethambutol`   | E            | 20 mg/kg         | 1 g            |
| `Streptomycin` | S            | 15 mg/kg         | 1 g            |

### Recommended Treatment Regimens

Two phases:

1. **Intensive phase**: To rapidly eliminate the majority of organisms and to prevent the emergence of drug resistance
2. **Continuation phase**: To eradicate the dormant organisms.

| TB Diagnostic Catgory | TB cases                                                                                                                                                                                                                                       | Regimen                                                    |                    |
| :-------------------- | :--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :--------------------------------------------------------- | :----------------- |
|                       |                                                                                                                                                                                                                                                | Intensive phase                                            | Continuation phase |
| **I**                 | - **New smear positive pulmonary TB** <br/>- New **smear negative** pulmonary TB with **extensive parenchymal involvement** <br/>- Severe forms of **extra-pulmonary TB** (other than TB meningitis) <br/>- Severe **concomitant HIV** disease | `2HRZE`                                                    | `4HR`              |
| **I**                 | **TB meningitis** / **Disseminated TB** disease                                                                                                                                                                                                | `2HRZE(S)`                                                 | `7HRE`             |
| **II**                | - relapse <br/>- treatment after interruption<br/>- treatment failure                                                                                                                                                                          | `2HRZES`/`1HRZE`                                           | `5HRE`             |
| **III**               | - New **smear negative** pulmonary TB (other than in category I)<br/>- Less severe forms of **extra-pulmonary TB**                                                                                                                             | `2HRZ`                                                     | `4HR`              |
| **IV**                | - **Chronic and Multi-drug resistant TB**                                                                                                                                                                                                      | Specially designed standardized or individualized regimens |                    |
